BR0316290A - Método de tratar cistite intersticial - Google Patents

Método de tratar cistite intersticial

Info

Publication number
BR0316290A
BR0316290A BR0316290-7A BR0316290A BR0316290A BR 0316290 A BR0316290 A BR 0316290A BR 0316290 A BR0316290 A BR 0316290A BR 0316290 A BR0316290 A BR 0316290A
Authority
BR
Brazil
Prior art keywords
interstitial cystitis
modulation
treatment
methods
treating
Prior art date
Application number
BR0316290-7A
Other languages
English (en)
Inventor
Timothy C Fong
Alexis E Te
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of BR0316290A publication Critical patent/BR0316290A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODO DE TRATAR CISTITE INTERSTICIAL". Os métodos e composições referem-se ao tratamento de distúrbios da bexiga. Em particular, os métodos provêem o tratamento de cistite intersticial e distúrbios relacionados. Os métodos ainda compreendem o tratamento para afetar várias manifestações associadas com a cistite intersticial, incluindo, a redução da liberação de histamina, a modulação da expressão de substância P, a modulação da expressão do fator de crescimento de nervo, a modulação dos níveis de várias citocinas, e a manutenção da integridade da barreira urina/ sangue.
BR0316290-7A 2002-11-15 2003-11-17 Método de tratar cistite intersticial BR0316290A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42668402P 2002-11-15 2002-11-15
US47083903P 2003-05-15 2003-05-15
PCT/US2003/037043 WO2004045554A2 (en) 2002-11-15 2003-11-17 Cytomodulating peptides for treating interstitial cystitis

Publications (1)

Publication Number Publication Date
BR0316290A true BR0316290A (pt) 2005-10-11

Family

ID=32329122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316290-7A BR0316290A (pt) 2002-11-15 2003-11-17 Método de tratar cistite intersticial

Country Status (13)

Country Link
US (1) US7671026B2 (pt)
EP (1) EP1594519A4 (pt)
JP (1) JP2006516546A (pt)
KR (1) KR20050086676A (pt)
AU (1) AU2003294357A1 (pt)
BR (1) BR0316290A (pt)
CA (1) CA2505922A1 (pt)
CO (1) CO5640064A2 (pt)
MA (1) MA27607A1 (pt)
MX (1) MXPA05005101A (pt)
NO (1) NO20052814L (pt)
RU (1) RU2005118425A (pt)
WO (1) WO2004045554A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014484A1 (en) * 2006-07-27 2008-01-31 University Of Maryland, Baltimore Cellular receptor for antiproliferative factor
BRPI0906404B8 (pt) * 2008-01-24 2021-05-25 Univ Louisiana State construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
US8912146B2 (en) 2008-08-18 2014-12-16 University Of Maryland, Baltimore Derivatives of APF and methods of use
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CA2915960A1 (en) 2013-06-17 2014-12-24 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2947508A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US10859579B2 (en) * 2016-03-31 2020-12-08 William Beaumont Hospital Methods for detecting, diagnosing and treating ulcerative interstitial cystitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902786T2 (xx) * 1997-04-11 2000-06-21 Sangstat Medical Corporation Ba����kl�k sistemi faaliyetinin d�zene sokulmas� ve iltihaplanman�n durdurulmas� i�in lipofilik peptidlerin h�cre yap�s�n�n d�zene konulmas�.
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
JP2002512259A (ja) * 1998-04-17 2002-04-23 ユニバーシティ・オブ・メリーランド， ボルティモア 組換えヘパリン結合性上皮成長因子様成長因子（ｈｂ−ｅｇｆ）による間質性膀胱炎の治療方法
MXPA05003063A (es) * 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.

Also Published As

Publication number Publication date
CO5640064A2 (es) 2006-05-31
US20060194738A1 (en) 2006-08-31
EP1594519A4 (en) 2006-08-16
KR20050086676A (ko) 2005-08-30
AU2003294357A1 (en) 2004-06-15
WO2004045554A2 (en) 2004-06-03
EP1594519A2 (en) 2005-11-16
US7671026B2 (en) 2010-03-02
NO20052814D0 (no) 2005-06-10
WO2004045554A3 (en) 2005-07-07
RU2005118425A (ru) 2006-02-10
NO20052814L (no) 2005-08-04
CA2505922A1 (en) 2004-06-03
JP2006516546A (ja) 2006-07-06
MXPA05005101A (es) 2005-09-08
MA27607A1 (fr) 2005-11-01

Similar Documents

Publication Publication Date Title
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
NO20052814L (no) Cytomodulerende peptider for behandling av interstitielle cystitt
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
DK1885382T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af cardiovaskulære tilstande
WO2004066990A3 (en) Methods of treating lower urinary tract disorders using sodium channel modulators
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
DK1599575T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af kardiovaskulære tilstande
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
WO2005107730A3 (en) Cysteamines for treating complications of hypercholesterolemia and diabetes
ATE291433T1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
DE60213386D1 (de) Geldanamycinderivate zur krebsbehandlung
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2002015920A3 (en) Treatment of hyperproliferative diseases
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
WO2009016451A8 (en) Method and compound for the treatment of articular diseases or articular pain, or for the treatment of skin for aesthetic or other purposes, and the method of preparation of the compound
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
BR0311161A (pt) Método de tratamento de diabetes
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
WO2005060960A3 (en) Use of histamine to treat bone disease
AR060952A1 (es) Microfono implantable para el tratamiento de desordenes neurologicos
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired